Axim Biotechnologies Inc (AXIM)

OTC Markets
0.67
0.00(0.00%)
After Hours
0.67
+0.01(+1.52%)
- Delayed Data
  • Volume:
    36,869
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    0.65 - 0.68

AXIM Overview

Prev. Close
0.67
Day's Range
0.65-0.68
Revenue
40K
Open
0.68
52 wk Range
0.39-1.22
EPS
-0.07
Volume
36,869
Market Cap
89.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
137,073
P/E Ratio
-
Beta
-0.14
1-Year Change
-4.29%
Shares Outstanding
133,261,989
Next Earnings Date
-
What is your sentiment on Axim Biotechnologies Inc?
or
Market is currently closed. Voting is open during market hours.

Axim Biotechnologies Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellBuyBuySell
Technical IndicatorsStrong SellStrong SellSellStrong BuySell
SummaryStrong SellStrong SellNeutralStrong BuySell

Axim Biotechnologies Inc Company Profile

Axim Biotechnologies Inc Company Profile

Employees
5

AXIM Biotechnologies, Inc., a preclinical stage research and development company focuses on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company is developing NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies to prevent SARS-CoV-2 from entering the host cells; and ImmunoPass, a rapid serological diagnostic test that measures SARS-CoV-2 neutralizing antibodies within 10 minutes. It is also developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Read More
  • Any news on when there Covid test for Antibodies will be FDA approved?
    0
    • what happened here?
      0
      • https://www.globenewswire.com/fr/news-release/2020/07/15/2062560/0/en/AXIM-Biotechnologies-Unveils-First-in-Class-COVID-19-Rapid-Diagnostic-Test-for-Neutralizing-Antibodies-and-Files-Pre-Emergency-Use-Authorization-with-the-FDA.html
        0
        • https://www.biospace.com/article/releases/axim-biotechnologies-files-for-patent-for-unique-biomarker-for-early-detection-of-cancer-in-blood/
          0
          • https://emerginggrowth.com/aximr-biotechnologies-inc-otcqb-axim-begins-pre-clinical-pharmacokinetic-animal-drug-studies-on-spx-1009/
            0
            • This company is running tests using animals for their clinical trials.
              0
              • https://www.prnewswire.com/news-releases/medical-marijuana-inc-investment-company-axim-biotechnologies-files-patent-for-unique-early-detection-cancer-biomarker-301063178.html
                1
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.